Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients.
Seth, Ashok
Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients. [electronic resource] - Indian heart journal - 302-8 p. digital
Publication Type: Journal Article; Multicenter Study
2213-3763
10.1016/j.ihj.2014.03.007 doi
Antineoplastic Agents
Coronary Angiography
Coronary Artery Disease--diagnostic imaging
Drug-Eluting Stents
Everolimus
Female
Follow-Up Studies
Humans
Immunosuppressive Agents--pharmacology
Incidence
India--epidemiology
Kaplan-Meier Estimate
Male
Middle Aged
Myocardial Infarction--diagnostic imaging
Percutaneous Coronary Intervention--adverse effects
Postoperative Complications--diagnostic imaging
Prognosis
Prospective Studies
Prosthesis Design
Risk Assessment
Risk Factors
Sirolimus--analogs & derivatives
Survival Rate--trends
Time Factors
Treatment Outcome
Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients. [electronic resource] - Indian heart journal - 302-8 p. digital
Publication Type: Journal Article; Multicenter Study
2213-3763
10.1016/j.ihj.2014.03.007 doi
Antineoplastic Agents
Coronary Angiography
Coronary Artery Disease--diagnostic imaging
Drug-Eluting Stents
Everolimus
Female
Follow-Up Studies
Humans
Immunosuppressive Agents--pharmacology
Incidence
India--epidemiology
Kaplan-Meier Estimate
Male
Middle Aged
Myocardial Infarction--diagnostic imaging
Percutaneous Coronary Intervention--adverse effects
Postoperative Complications--diagnostic imaging
Prognosis
Prospective Studies
Prosthesis Design
Risk Assessment
Risk Factors
Sirolimus--analogs & derivatives
Survival Rate--trends
Time Factors
Treatment Outcome